Abstract
Neuroblastoma (NB), a childhood radiosensitive tumor, is very aggressive and malignant; in its disseminated form, despite very intensive chemotherapy, prognosis continues to be dismal. Owing to its capacity to concentrate in NB lesions, large doses of 131-I-MIBG, have given very encouraging therapeutic results in patients resistant to conventional therapy as well as at diagnosis.We recently reported the first attempt in combination therapy (CO-TH) using 131-I-MIBG and cisplatin. This new form of CO-TH appears very effective in obtaining a rapid and excellent response in relapsed patients.In this report, we describe the results of further experience with CO-TH in disseminated NB. We have attempted to verify to what extent interaction between the effects of the two agents may produce therapeutic benefit, and we have sought the optimization of CO-TH use.Three stage IV NB patients were treated with CO-TH. The following treatment schedule, was planned: day 1, cisplatin 50 mg/m2 i.v. over 6 h; day 2, 131-I-MIBG 100—130 mCi at high specific activity (- 1.1 Gbq/mg) i.v. over 6 h followed, a week later, by the same treatment combination.The therapeutic results were encouraging. However, hematological toxicity continued to represent a major limiting factor. In view of the overall effectiveness of CO-TH, at the price of lasting hematological toxicity, it may be indicated as a consolidationregimen some time before conditioning chemotherapy for autologous bone marrow transplantation.
Similar content being viewed by others
References
Heppner GH: Tumor heterogeneity. Cancer Res 44: 2259–2265, 1984
Woodruff MFA: Cellular heterogenity in tumours. Br J Cancer 47: 589–594, 1983
Matthay KK: An overview on the treatment of neuroblastoma. J Nucl Biol Med 35: 179–182, 1991
Troncone L, Riccardi R, Montemaggi P, Rufini V, Lasorella A, Mastrangelo R: Treatment of neuroblastoma with 131-I-Metaiodobenzylguanidine. Med Pediatr Oncol 15: 220–223, 1987
Mastrangelo R: The treatment of neuroblastoma with 131-I-MIBG [editorial]. Med Pediatr Oncol 15: 157–158, 1987
Mastrangelo R, Troncone L, Lasorella A, Riccardi R, Montemaggi P, Rufini V: 131-I-Metaiodobenzylguanidine in the treatment of neuroblastoma at diagnosis. Am J Ped Hematol Oncol 11: 28–31, 1989
Mastrangelo R, Lasorella A, Iavarone A, Rufini V, Troncone L, Danza F, Riccardi R: Critical observation on neuroblastoma treatment with 131-I-metaiodobenzylguanidine at diagnosis. Med Pediatr Oncol 21: 411–415, 1993
Mastrangelo R, Tornesello A, Riccardi R, Lasorella A, Mastrangelo S, Mancini A, Rufini V, Troncone L: A new approach in the treatment of stage IV neuroblastoma using a combination on 131-I-Metaiodobenzylguanidine (MIBG) and cisplatin. Eur J Cancer 4: 606–611, 1995
Dewit L: Combined treatment of radioation and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Rad Oncol Biol Phys 13: 403–426, 1987
De Kraker J, Hoefnagel CA, Caron H, Voute PA, Tiel van Buul MMC, Valdes Olmos R: Targeted radiotherapy with iodine-131-metaiodobenzylguanidine (MIBG) as first line treatment of neuroblastoma advanced disease patients. SIOP XXVI Meeting, Med Pediatr Oncol 23: 179, 1994
Reed E, Kohn KW: Platinum analogues. In: Chabner BA, Collins JM (eds) Cancer Chemotherapy. Principles & Practice. J.B.Lippincott, Philadelphia, 1990, pp 465–490
Steel GG: The search for therapeutic gain in the combination of radiotherapy and chemotherapy. Radiot Oncol 11: 31–53, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mastrangelo, R., Tornesello, A., Lasorella, A. et al. Optimal use of the 131-I-metaiodobenzylguanidine and cisplatin combination in advanced neuroblastoma. J Neurooncol 31, 153–158 (1997). https://doi.org/10.1023/A:1005770405844
Issue Date:
DOI: https://doi.org/10.1023/A:1005770405844